Complete remission through icotinib treatment in Non-small cell lung cancer epidermal growth factor receptor mutation patient with brain metastasis: A case report

Wang, Tao; Wang, Ruimin; Dong, Zhouhuan; Liang, Naichao; Chang, Ping

doi:10.1515/med-2016-0003

Cited by 3 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the 24 publications, one publication [ 19 ] has no data for DCRs; DCRs were 100% in EGFR mutant patients and EGFR wild type patients in two publications [ 12 , 20 ]. After excluding these 3 publications, 21 publications having 1127 patients including 750 EGFR mutant patients and 377 EGFR wild type patients were enrolled in meta-analysis for DCRs.…”

Section: Resultsmentioning

confidence: 99%

Clinical efficacy of icotinib in lung cancer patients with differentEGFRmutation status: a meta-analysis

Wang²,

et al. 2017

Oncotarget

View full text Add to dashboard Cite

Icotinib is a novel and the third listed epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), which exerts a good anti-tumor efficacy on non-small cell lung cancer (NSCLC). The efficacy of EGFR-TKIs has been shown to be associated with the EGFR mutation status, especially exon 19 deletion (19Del) and exon 21 L858R mutation. Therefore, a meta-analysis was performed to assess the efficacy of icotinib in NSCLC patients harboring EGFR mutations (19Del or L858R) and wild type (19Del and L858R loci wild type). A total of 24 studies were included for comparing the objective response rate (ORR) in the EGFR wild type and mutant patients treated with icotinib. The ORRs of EGFR mutant patients (19Del or L858R) are better than those of EGFR wild type patients (OR = 7.03(5.09–9.71), P < 0.00001). The pooling ORs from 21 studies on the disease control rate (DCR) in EGFR mutant patients are better than those of EGFR wild type patients (OR = 10.54(5.72–19.43), P < 0.00001). Moreover, the ORRs of EGFR 19Del patients are better than those of EGFR L858R patients after pooling ORs of 12 studies (OR = 2.04(1.12–3.73), P = 0.019). However, there was no significant difference on DCRs of EGFR 19Del patients and those of EGFR L858R patients (OR = 2.01(0.94–4.32), P = 0.072). Our findings indicated that compared with EGFR wild type patients, EGFR mutant patients have better ORRs and DCRs after icotinib treatment; EGFR 19Del patients treated with icotinib have better ORRs than EGFR L858R patients. EGFR mutation status is a useful biomarker for the evaluation of icotinib efficacy in NSCLC patients.

show abstract

Section: Resultsmentioning

confidence: 99%

Clinical efficacy of icotinib in lung cancer patients with differentEGFRmutation status: a meta-analysis

Wang²,

et al. 2017

Oncotarget

View full text Add to dashboard Cite

show abstract

“…Furthermore, 19-Del and 21-L858R mutations are associated with distinguishing clinical characteristics [11]. A previous study has revealed that the efficacy of EGFR-TKIs are associated with the EGFR mutations, especially exon 19 and exon 21 that are sensitive to targeted drug therapies [12][13][14][15]. Moreover, patients with 19-Del showed better clinical outcomes than those with 21-L858R when treated with EGFR-TKIs [16][17][18][19][20].…”

Section: Introductionmentioning

confidence: 99%

Efficacy of Icotinib, an EGFR Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients with Exon 19 Deletion and Exon 21 L858R: A Retrospective Analysis in China

et al. 2021

View full text Add to dashboard Cite

Introduction: The effect of icotinib on non-small cell lung cancer (NSCLC) patients with EGFR exon 19 deletions (19-Del) or L858R point mutation in exon 21 (21-L858R) remains inconsistent. This study aimed to evaluate the efficacy and safety of icotinib in patients with advanced NSCLC harboring these 2 EGFR mutations. Methods: We retrospectively assessed the clinical effects of first-line icotinib on advanced NSCLC patients with 2 classic EGFR mutations. Kinase activity assays were used to reaffirm the preclinical efficacy. Results: Among 2,757 patients, 2,365 (86%) harbored 19-Del (1,346/2,757, 49%) or 21-L858R (1,019/2,757, 37%) mutation. Patients with 19-Del had a higher response rate (ORR; 67.8 vs. 62.1%; p = 0.0039) and disease control rate (98.5 vs. 97.2%; p = 0.0223) than those with 21-L858R mutation. The median progression-free survival (PFS) in the 19-Del group (22.3 months, 95% confidence interval [CI]: 21.3–23.4) was significantly longer than that in the 21-L858R group (20.4 months, 95% CI: 19.5–21.7) (p = 0.004). In multivariate analysis, mutation types, clinical stage, and smoking history were significant factors for PFS. Additionally, an in vitro study indicated the 50% inhibitory concentrations (IC50) of icotinib was lower for EGFR 19-Del than 21-L858R. Conclusion: These results suggest that EGFR 19-Del confers superior PFS and response to the icotinib treatment compared to 21-L858R.

show abstract

Icotinib

2016

Reactions Weekly

View full text Add to dashboard Cite

Complete remission through icotinib treatment in Non-small cell lung cancer epidermal growth factor receptor mutation patient with brain metastasis: A case report

Cited by 3 publications

References 27 publications

Clinical efficacy of icotinib in lung cancer patients with differentEGFRmutation status: a meta-analysis

Clinical efficacy of icotinib in lung cancer patients with differentEGFRmutation status: a meta-analysis

Efficacy of Icotinib, an EGFR Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients with Exon 19 Deletion and Exon 21 L858R: A Retrospective Analysis in China

Icotinib

Contact Info

Product

Resources

About